http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2013118723-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2810-6018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10332 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-861 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-761 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861 |
| filingDate | 2011-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2013118723-A |
| titleOfInvention | ONCOLITIC Adenovirus VECTORS CODING MONOCLONAL ANTIBODIES AGAINST CTLA-4 |
| abstract | 1. Oncolytic adenovirus vector, including: 1) a backbone from the nucleic acid of the adenovirus of the 5th serotype (Ad5) containing a capsid modification, 2) a deletion of 24 (D24) in the Rb-binding constant region-2 E1, and 3) the nucleic acid sequence encoding a fully human monoclonal antibody specific for CTLA-4 (mAb aCTLA), at the site of the deleted gp19k / 6.7 K adenoviral genes in the E3.2 region. The oncolytic adenoviral vector according to claim 1, further comprising one or more sites selected from the group consisting of E2, E4 and late sites. The oncolytic adenoviral vector of claim 1, wherein the wild-type region is located in front of the E1.4 region. The oncolytic adenoviral vector of claim 1, wherein the E1 region includes a viral packaging signal. The oncolytic adenoviral vector of claim 1, wherein the nucleic acid sequence encoding aCTLA mAb is under the control of the E3.6 viral promoter. The oncolytic adenoviral vector of claim 1, which further comprises a nucleic acid sequence encoding a tumor-specific human telomerase reverse transcriptase (hTERT) promoter or an E2F promoter in front of the El.7 region. The oncolytic adenoviral vector of claim 1, further comprising a CpG site in the viral backbone. The oncolytic adenoviral vector according to claim 7, in which the CpG site is located on the plot EZ.9. The oncolytic adenoviral vector of claim 1, wherein the E4 region is of the wild type. The oncolytic adenoviral vector of claim 1, wherein the capsid modification is Ad5 / 3 chimerism, insertion of an integrin binding site (RGD) and / or modification of heparansulf binding |
| priorityDate | 2010-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 45.